Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CG | P48736 | 1/20 | 0.33 |
| ▸ | PDE5A | O76074 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24983903 | 0.87 | PIK3CG (0.35) | PIK3CG | |
| SCHEMBL21937448 | 0.80 | PIK3CG (0.45) | PIK3CG | |
| SCHEMBL23744915 | 0.73 | PIK3CG (0.32) | PIK3CG | |
| SCHEMBL22849538 | 0.70 | PIK3CG (0.31) | PIK3CGPOLB | |
| SCHEMBL25054373 | 0.70 | PDE5A (0.33) | PDE5APOLB | |
| SCHEMBL19677948 | 0.69 | KDM4E (0.33) | PIK3CGPDE5A | |
| SCHEMBL23696304 | 0.68 | SMPD3 (0.46) | PIK3CGPOLB | |
| SCHEMBL6860396 | 0.66 | PIK3CG (0.41) | PIK3CG | |
| SCHEMBL26199755 | 0.66 | TLR8 (0.34) | — | |
| SCHEMBL25027608 | 0.65 | NOS3 (0.39) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230303526-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-09-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230303526-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | PIK3CG 354/4885PDE5A 3291/4885POLB 2088/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.